Decision Resources, Inc., one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that sales of Genentech/Roche/Chugai's Herceptin (trastuzumab) will nearly triple, reaching $3.3 billion in 2015, following positive data from several Phase III clinical trials that show improved disease-free survival of breast cancer patients.

The new Pharmacor report entitled Breast Cancer finds that growth in both breast cancer market segments -- chemotherapy and hormonal treatments -- will be driven by the expansion of established agents, particularly Herceptin and Novartis's Femara (letrozole), from the metastatic into the adjuvant setting. The report also finds that the chemotherapy market in the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan will be bolstered by the use of new drugs, including GlaxoSmithKline's targeted agent Tykerb (lapatinib), which is expected to launch in 2007.

"The value of the adjuvant market, in which Herceptin and Femara are being incorporated, is higher than that of the metastatic market because the patient pool is larger and the duration of therapy is longer," said Mary Argent-Katwala, Ph.D., analyst at Decision Resources, Inc. "In addition to the growth these two well-established drugs will bring, we forecast that the launch of new agents, most notably Tykerb and Genentech/Roche/Chugai's Avastin (bevacizumab), will help to bolster the market during the 2010 to 2015 time frame, a period when several key patent expiries will limit overall annual market growth."

About Breast Cancer

Breast cancer is the most common cancer in women worldwide, with more than 2 million prevalent cases in the major markets. Although the incidence of the disease is rising, more women are now surviving the disease, owing to advances in screening and treatment.

About Decision Resources

Decision Resources, Inc. ( is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Elizabeth Marshall   Decision Resources, Inc.   781-296-2563 

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-2563,

Overall Positive Earnings Allow Hospital Expansion in Omaha

View Now